CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 547 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
9-Isopropylolomoucine
CAS:9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.Fórmula:C17H22N6OPureza:99.82%Cor e Forma:SolidPeso molecular:326.4Ref: TM-T23589
1mg315,00€1mL*10mM (DMSO)607,00€5mg745,00€10mg1.018,00€25mg1.431,00€50mg1.783,00€100mg2.250,00€500mg4.410,00€SRX3177
CAS:SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.Fórmula:C31H32N6O4SPureza:99.16%Cor e Forma:SolidPeso molecular:584.69Ref: TM-T69742
1mg70,00€5mg150,00€1mL*10mM (DMSO)178,00€10mg215,00€25mg358,00€50mg517,00€100mg707,00€CLK-IN-T3
CAS:CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.Fórmula:C28H30N6O2Pureza:99.61%Cor e Forma:SolidPeso molecular:482.58Ref: TM-T14980
1mg47,00€2mg62,00€5mg92,00€10mg160,00€25mg289,00€50mg505,00€100mg787,00€200mg1.063,00€Cdc7-IN-7c
CAS:Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.Fórmula:C15H17N5OSPureza:98.19% - 99.22%Cor e Forma:SolidPeso molecular:315.39Ref: TM-T23867
1mg315,00€1mL*10mM (DMSO)600,00€5mg745,00€10mg1.018,00€25mg1.431,00€50mg1.783,00€100mg2.250,00€500mg4.410,00€PS423
CAS:PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.Fórmula:C25H23F3O9Pureza:98.81% - 99.26%Cor e Forma:SolidPeso molecular:524.44EHT 1610
CAS:EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.Fórmula:C18H14FN5O2SPureza:98.43%Cor e Forma:SolidPeso molecular:383.4ML 315
CAS:ML 315 is a selective Clk and DYRK inhibitor with potential anticancer activity for the study of neurological disorders.Fórmula:C18H13Cl2N3O2Pureza:99.08%Cor e Forma:SolidPeso molecular:374.22Abemaciclib metabolite M20
CAS:Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。Fórmula:C27H32F2N8OPureza:98.1% - 99.08%Cor e Forma:SolidPeso molecular:522.59Ryuvidine
CAS:Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.Fórmula:C15H12N2O2SPureza:98.6%Cor e Forma:SolidPeso molecular:284.33(S)-PF-06873600
CAS:(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.Fórmula:C20H27F2N5O4SPureza:98.59%Cor e Forma:SolidPeso molecular:471.52Cdk2 Inhibitor II
CAS:Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.Fórmula:C14H11BrN4O3SPureza:97.27%Cor e Forma:SolidPeso molecular:395.23CDK-IN-2
CAS:CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).Fórmula:C18H19ClFN3O2Pureza:99.67%Cor e Forma:SolidPeso molecular:363.81Ref: TM-TQ0078
1mg38,00€2mg51,00€1mL*10mM (DMSO)92,00€5mg96,00€10mg138,00€25mg258,00€50mg376,00€100mg532,00€500mg1.063,00€dCeMM2
CAS:dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.Fórmula:C16H11ClN6OSPureza:99.68%Cor e Forma:SolidPeso molecular:370.82Ref: TM-T61477
1mg34,00€5mg74,00€1mL*10mM (DMSO)104,00€10mg113,00€25mg236,00€50mg404,00€100mg600,00€500mg1.279,00€DIF-3
CAS:DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.Fórmula:C13H17ClO4Pureza:99.57%Cor e Forma:SolidPeso molecular:272.72Ref: TM-T60485
1mg96,00€1mL*10mM (DMSO)205,00€5mg222,00€10mg333,00€25mg557,00€50mg795,00€100mg1.071,00€500mg2.187,00€Inixaciclib
CAS:Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.Fórmula:C26H30F2N6OCor e Forma:SolidPeso molecular:480.55Lerociclib
CAS:Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.Fórmula:C26H34N8OPureza:99%Cor e Forma:SolidPeso molecular:474.6Palbociclib orotate
CAS:Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.Fórmula:C29H33N9O6Pureza:98%Cor e Forma:SolidPeso molecular:603.63CDK4-IN-2
CAS:CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].Fórmula:C22H26F2N6O4SPureza:98%Cor e Forma:SolidPeso molecular:508.54CDK-IN-11
CAS:CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].Fórmula:C25H21BrN4O2Cor e Forma:SolidPeso molecular:489.36EHT 5372
CAS:EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.Fórmula:C17H11Cl2N5OSCor e Forma:SolidPeso molecular:404.275-Iodo-indirubin-3'-monoxime
CAS:5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50sFórmula:C16H10IN3O2Cor e Forma:SolidPeso molecular:403.17Leucettinib-92
CAS:Leucettinib-92 is a multi-kinase inhibitor of DYRK and CLK families with differential nanomolar activity, supporting studies of kinase signaling regulation.Fórmula:C21H22N4OSPureza:98%Cor e Forma:SolidPeso molecular:378.49CDK9-IN-8
CAS:CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).Fórmula:C31H32FN7O3Pureza:99.54%Cor e Forma:SolidPeso molecular:569.63Voruciclib hydrochloride
CAS:Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).Fórmula:C22H20Cl2F3NO5Pureza:98%Cor e Forma:SolidPeso molecular:506.3Bisindolylmaleimide X hydrochloride
CAS:Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).Fórmula:C26H25ClN4O2Pureza:99.23%Cor e Forma:SolidPeso molecular:460.96Senexin C
CAS:Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.Fórmula:C28H27N5OPureza:98.06%Cor e Forma:SolidPeso molecular:449.55CDK9-IN-9
CAS:CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).Fórmula:C22H23F2N5O2SPureza:98%Cor e Forma:SolidPeso molecular:459.51DCB-3503
CAS:DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.Fórmula:C24H27NO5Cor e Forma:SolidPeso molecular:409.47CDK9-IN-23
CAS:CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].Fórmula:C22H25ClN4O3Pureza:98%Cor e Forma:SolidPeso molecular:428.91(2S,3R)-Voruciclib
CAS:(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.Fórmula:C22H19ClF3NO5Pureza:98%Cor e Forma:SolidPeso molecular:469.84KM05382
CAS:KM05382 inhibits CDK9 and the transcription of GAPDH.Fórmula:C20H19ClN2O3S2Cor e Forma:SolidPeso molecular:434.96NU6300
CAS:NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.Fórmula:C20H23N5O3SPureza:96.08%Cor e Forma:SolidPeso molecular:413.49SHP2/CDK4-IN-1
CAS:SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.Fórmula:C33H35ClF2N10OSCor e Forma:SolidPeso molecular:693.21HQ005
CAS:HQ005, a potent CCNK degrader, exhibits an impressive DC50 value of 0.041 µM and functions as a molecular-glue degrader.Fórmula:C15H15N5O2S2Cor e Forma:SolidPeso molecular:361.44(S)-Cdc7-IN-18
CAS:'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47CDK/HDAC-IN-3
CAS:CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,Fórmula:C24H18Cl2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:509.34CDK4/6-IN-17
CAS:CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.Fórmula:C27H28F4N8Pureza:98%Cor e Forma:SolidPeso molecular:540.56CDK8-IN-3
CAS:CDK8-IN-3 is an inhibitor of CDK8.Fórmula:C22H23N5O2Pureza:98%Cor e Forma:SolidPeso molecular:389.45CDK9-IN-29
CAS:CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.Fórmula:C29H33F2N5O4Pureza:98%Cor e Forma:SolidPeso molecular:553.6Xylocydine
CAS:Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.Fórmula:C12H14BrN5O5Cor e Forma:SolidPeso molecular:388.17CDK9-IN-2
CAS:CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.Fórmula:C23H25ClFN5Pureza:99%Cor e Forma:SolidPeso molecular:425.93Ref: TM-T14918
1mg84,00€5mg177,00€1mL*10mM (DMSO)195,00€10mg266,00€25mg460,00€50mg668,00€100mg945,00€Cdc7-IN-12
CAS:Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).Fórmula:C16H14N2O2SCor e Forma:SolidPeso molecular:298.36Senexin A hydrochloride
CAS:Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].Fórmula:C17H15ClN4Cor e Forma:SolidPeso molecular:310.78QR-6401
CAS:QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/Fórmula:C19H23N5O3Pureza:98%Cor e Forma:SolidPeso molecular:369.42CDK4/6-IN-15
CAS:CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.Fórmula:C21H27FN8SCor e Forma:SolidPeso molecular:442.56SZ-015268
CAS:SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.Fórmula:C25H38N8O3Cor e Forma:SolidPeso molecular:498.62Tacaciclib
CAS:Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].Fórmula:C30H36N6O3Pureza:98%Cor e Forma:SolidPeso molecular:528.65LDC3140
CAS:LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).Fórmula:C23H33N7OPureza:98%Cor e Forma:SolidPeso molecular:423.55PF-6808472
CAS:PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.Fórmula:C25H27FN8O3SPureza:99.02%Cor e Forma:SolidPeso molecular:538.6CDK9-IN-19
CAS:CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.Fórmula:C26H22F2N4O5Cor e Forma:SolidPeso molecular:508.47
